Argentina
Reimbursed Care Access
Argentina has an established regulatory framework for specific psychedelic derivatives, specifically Esketamine, while maintaining strict prohibition for classic hallucinogens like Psilocybin and MDMA.
📜History of research in Argentina
The history of psychedelic research in Argentina traces international scientific developments into local psychiatry and anthropology rather than a long independent tradition of clinical trials. Globally, LSD was first synthesised by Albert Hofmann at Sandoz in 1938 and its psychoactive properties were described in 1943; Sandoz distributed LSD (marketed as Delysid) to psychiatric institutions worldwide in the late 1940s. Argentine psychiatrists and neuroscientists, working in academic hospitals and psychiatric institutes in Buenos Aires and other provincial centres, were exposed to these international reports and case series during the 1950s and 1960s, and occasional clinical and observational uses were reported in the period before international control regimes tightened access.
The international control of many serotonergic psychedelics after the 1960s and the entry into force of the 1971 UN Convention on Psychotropic Substances, paired with Argentina's own national drug legislation, substantially restricted clinical and research use. Law 23.737 (the national narcotics law, enacted in 1989) and related provisions criminalise unauthorised manufacture, possession and distribution of many classical psychedelics. Nonetheless, academic and anthropological interest in plant-based medicines such as ayahuasca, and in indigenous practices, continued to be documented by social scientists and clinicians through ethnographic work and case reports.
From the 2000s onward a slower, more cautious revival of scientific and clinical interest has taken place in Argentina in parallel with the global psychedelic renaissance. This revival has been led by university departments of psychiatry, neuroscience laboratories within CONICET-affiliated institutions and independent clinicians and researchers who pursue ethnobotanical studies, observational work, preclinical pharmacology and pilot clinical projects where regulatory permissions can be obtained. The growth of ayahuasca and Santo Daime communities in Argentina and neighbouring countries also drew local attention from anthropologists, public health researchers and legal scholars assessing the interplay between sacramental use, public safety and drug policy.
In the most recent decade the landscape has been one of fragmented activity rather than a centralised national programme: small academic groups investigate mechanistic neuroscience questions, clinicians publish case series and qualitative studies, and civil society organisations promote training, harm-reduction and dialogue with regulators. Regulatory oversight of any interventional work with scheduled substances is exercised by Argentina's ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) and requires formal authorisation; as a result, most Argentine activity to date has been observational, preclinical, or conducted under tightly controlled, ad hoc approvals rather than large multicentre clinical trials.
🔬Research Focus
Current research strengths in Argentina lie in neuroscience, psychiatry, addiction medicine and anthropological studies of plant medicine use. University and CONICET-affiliated neuropharmacology laboratories have the expertise to study receptor pharmacology, biomarkers and neuroimaging correlates of serotonergic compounds, while hospital-based psychiatry departments contribute clinical insight into treatment-resistant depression, substance use disorders and trauma-related conditions. Ethnographic and public-health research has documented the social, ritual and legal dimensions of ayahuasca and other sacramental practices within Argentine communities.
Specific compounds that receive the most local attention are ayahuasca/DMT (through ethnobotanical and public-health lenses), classical serotonergic psychedelics such as psilocybin and LSD in preclinical and conceptual clinical contexts, and MDMA primarily in discussions of PTSD and trauma therapy. To date, most activity focuses on proof-of-concept work, observational cohorts, qualitative research and preclinical studies; large-scale, ANMAT-authorised phase 2/3 clinical trials are limited, so clinical priorities remain exploratory research into depression, addiction and trauma-related disorders with an emphasis on building regulatory, ethical and training capacity prior to wider therapeutic implementation.
🏆Key Milestones
🚀Future Outlook
In the next 12–24 months it is reasonable to expect incremental growth rather than sudden expansion. Practical developments are likely to include additional observational cohorts, more formalised preclinical studies within CONICET and university laboratories, and a small number of ANMAT‑authorised pilot clinical trials or compassionate-use protocols where institutional review boards and regulators approve strict safeguards. International influences — notably regulatory progress in North America and Europe and the publication of larger multinational trials — will continue to inform Argentine researchers and regulators.
On the regulatory and policy side, ANMAT and institutional review boards are likely to clarify requirements for clinical research with scheduled substances, and civil-society groups will probably increase focused training in clinical, legal and ethical best practice. Legal ambiguity around sacramental use of plant medicines is expected to remain an active subject of scholarly and judicial attention, prompting more systematic public-health research and harm-reduction initiatives rather than immediate legislative overhaul.